Mario Sznol, MD

Professor Emeritus of Medicine (Medical Oncology and Hematology)

DownloadHi-Res Photo

Contact Info

About

Titles

Professor Emeritus of Medicine (Medical Oncology and Hematology)

Biography

Dr. Mario Sznol is Professor Emeritus of Medicine (Medical Oncology and Hematology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He recently joined the Sylvester Comprehensive Cancer Center in Miami where he supports coordination of immuno-oncology research efforts.

Last Updated on October 14, 2026.

Departments & Organizations

Human and Translational Immunology Program
Internal Medicine
K12 Calabresi Immuno-Oncology Training Program (IOTP)
SPORE in Skin Cancer
Yale Ventures

Education & Training

Fellow: Mount Sinai College of Medicine (1987)

Resident: Baylor College of Medicine (1985)

MD: Baylor College of Medicine (1982)

BA: Rice University (1979)

Board Certifications

Medical Oncology
Certification Organization
AB of Internal Medicine
Original Certification Date
1987
Internal Medicine
Certification Organization
AB of Internal Medicine
Original Certification Date
1985

Research

Overview

Dr. Sznol has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is currently Professor Emeritus of Medicine (Medical Oncology and Hematology) and joined the Sylvester Comprehensive Cancer Center in Miami where he supports coordination of immuno-oncology research efforts.

Medical Research Interests

Melanoma

ORCID
0000-0002-4359-8749

Research at a Glance

Yale Co-Authors

Frequent collaborators of Mario Sznol's published research.

Harriet Kluger, MD
View Full Profile
View 54 Common Publications
Ruth Halaban, PhD
View Full Profile
View 22 Common Publications
Antonella Bacchiocchi
View Full Profile
View 16 Common Publications
Lucia Jilaveanu, MD, PhD
View Full Profile
View 11 Common Publications
Scott Gettinger, MD
View Full Profile
View 10 Common Publications
David Rimm, MD, PhD
View Full Profile
View 9 Common Publications

Publications

2026

Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies
Lahav C, Dahan N, Harel M, Elon Y, Sela I, Geyer P, Schneider M, Muley T, Bacchiocchi A, Marte J, Floudas C, Halaban R, Sznol M, Christopoulos P, Gulley J. Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies. Journal Of Pharmaceutical And Biomedical Analysis 2026, 274: 117421. PMID: 41713118, PMCID: PMC13008497, DOI: 10.1016/j.jpba.2026.117421.
Peer-Reviewed Original Research
MeSH Keywords
Clonal determinants of organotropism and survival in metastatic uveal melanoma
Jones B, Hammes E, Demkowicz P, Matesva M, Pointdujour-Lim R, Sinard J, Bacchiocchi A, Halaban R, Bosenberg M, Sznol M, Kluger H, Bakhoum M. Clonal determinants of organotropism and survival in metastatic uveal melanoma. Npj Precision Oncology 2026, 10: 68. PMID: 41582235, PMCID: PMC12913882, DOI: 10.1038/s41698-026-01274-8.
Peer-Reviewed Original Research

2025

Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1
Tran T, Sánchez-Zuno G, Osmani L, Caulfield J, Valdez C, Piecychna M, Leng L, Armstrong M, Donnelly S, Bifulco C, Clister T, Kulkarni R, Zhang L, Sznol M, Jilaveanu L, Kluger H, Kang I, Bucala R. Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1. JCI Insight 2025, 10: e191539. PMID: 41122966, PMCID: PMC12581657, DOI: 10.1172/jci.insight.191539.
Peer-Reviewed Original Research
MeSH Keywords

2024

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Long G, Larkin J, Schadendorf D, Grob J, Lao C, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto P, Atkinson V, Postow M, Atkins M, Sznol M, Callahan M, Topalian S, Sosman J, Kotapati S, Thakkar P, Ritchings C, Benito M, Re S, Soleymani S, Hodi F. Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma. Journal Of Clinical Oncology 2024, 43: 938-948. PMID: 39504507, PMCID: PMC11895829, DOI: 10.1200/jco.24.00400.
Peer-Reviewed Original Research
Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
Li X, Liu T, Bacchiocchi A, Li M, Cheng W, Wittkop T, Mendez F, Wang Y, Tang P, Yao Q, Bosenberg M, Sznol M, Yan Q, Faham M, Weng L, Halaban R, Jin H, Hu Z. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction. EMBO Molecular Medicine 2024, 16: 12. PMID: 39164471, PMCID: PMC11393307, DOI: 10.1038/s44321-024-00115-0.
Peer-Reviewed Original Research
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, PMCID: PMC11809125, DOI: 10.1111/pcmr.13188.
Peer-Reviewed Original Research
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.
Peer-Reviewed Original Research
How Far We’ve Come
Sznol M, Weber J. How Far We’ve Come. The Cancer Journal 2024, 30: 47-47. PMID: 38527256, DOI: 10.1097/ppo.0000000000000710.
Peer-Reviewed Original Research
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.
Peer-Reviewed Original Research
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui M, Cooper T, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr S, Shaked Y. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 2024, 42: 253-265.e12. PMID: 38181798, PMCID: PMC10864002, DOI: 10.1016/j.ccell.2023.12.005.
Peer-Reviewed Original Research

See All Publications

News & Links

News

See All News

Related Links
- Meet Dr. Sznol
- Treatment for Metastatic Melanoma

Get In Touch

Contacts

mario.sznol@yale.edu

Contact Info

Titles

Biography

Departments & Organizations

Education & Training

Board Certifications

Medical Oncology

Internal Medicine

Overview

Medical Research Interests

ORCID

Research at a Glance

Yale Co-Authors

Harriet Kluger, MD

Ruth Halaban, PhD

Antonella Bacchiocchi

Lucia Jilaveanu, MD, PhD

Scott Gettinger, MD

David Rimm, MD, PhD

Publications

2026

2025

2024

News

YCC Standout Research, Clinical Care, and Staff Support Recognized

Twenty-Seven YSM Faculty Members Recognized for Highly Cited Research

Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting

Immunotherapy: Balancing Cancer Treatment Benefits and Risks

Related Links

Contacts